

Kenya Support for Pentavalent Vaccine

This Decision Letter sets out the Terms of a Programme.

1. Country: Kenya				
2. Grant number: 16-KEN-04c-X				
3. Date of Decision Letter: 26 April 2016				
4. Date of the Partnership Framework Agreement: 25 November 2014				
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 doses per vial, LIQUID				
8. Programme duration⁶: 2001 – 2017				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2001 - 2015	2016	2017	Total ⁷
Programme Budget (US\$)	159,621,044 ⁸	4,011,500	6,968,000	170,600,544
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁹				
Type of supplies to be purchased with Gavi funds in each year	2001 – 2015	2016		
Number of Pentavalent vaccines doses		2,136,500		
Number of AD syringes		2,307,500		
Annual Amounts (US\$)	159,621,044 ¹⁰	4,011,500		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-KEN-04c-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant fiscal year.

Type of supplies to be purchased with Country funds in each year	2016 – 2017
Number of vaccine doses	429,000
Value of vaccine doses (US\$)	770,944
Total co-financing payments (US\$) (including freight)	805,400

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May, annually
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
26 April 2016

Kenya Support for Pneumococcal Vaccine

This Decision Letter sets out the Terms of a Programme.

1. Country: Kenya				
2. Grant number: 16-KEN-12b-X				
3. Date of Decision Letter: 26 April 2016				
4. Date of the Partnership Framework Agreement: 25 November 2014				
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 doses per vial , LIQUID				
8. Programme duration¹: 2010 - 2017				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2010 - 2015	2016	2017	Total ²
Programme Budget (US\$)	153,460,753 ³	21,193,000	17,170,500	191,824,253
10. Vaccine introduction grant (in US\$): Not applicable.				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2010 - 2015	2016		
Number of Pneumococcal vaccines doses		4,324,000		
Number of AD syringes		4,803,900		
Annual Amounts (US\$)	153,460,753 ⁵	21,193,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-KEN-12b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant fiscal year.

Type of supplies to be purchased with Country funds in each year	2016 - 2017
Number of vaccine doses	522,800
Value of vaccine doses (US\$)	1,762,937
Total co-financing payments (US\$) (including freight)	1,801,450

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May, annually
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

26 April 2016

Kenya Support for Rotavirus Vaccine

This Decision Letter sets out the Terms of a Programme.

1. Country: Kenya				
2. Grant number: 16-KEN-13b-X				
3. Date of Decision Letter: 26 April 2016				
4. Date of the Partnership Framework Agreement: 25 November 2014				
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine				
6. Vaccine type: Rotavirus				
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose schedule				
8. Programme duration¹¹: 2014 – 2017				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2014 – 2015	2016	2017	Total ¹²
Programme Budget (US\$)	12,039,182 ¹³	4,515,500	6,560,500	23,115,182
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ¹⁴				
Type of supplies to be purchased with Gavi funds in each year	2014 – 2015	2016		
Number of Rotavirus vaccines doses		1,998,000		
Annual Amounts (US\$)	12,039,182 ¹⁵	4,515,500		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				

¹¹ This is the entire duration of the Programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹³ This is the consolidated amount for all previous years.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-KEN-13b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant fiscal year.

Type of supplies to be purchased with Country funds in each year	2016 – 2017
Number of vaccine doses	357,000
Value of vaccine doses (US\$)	784,549
Total co-financing payments (US\$) (including freight)	805,950

15. Operational support for campaigns: Not applicable


16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May, annually
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
26 April 2016

Kenya Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Kenya				
2. Grant number: 16-KEN-06b-X				
3. Date of Decision Letter: 26 April 2016				
4. Date of the Partnership Framework Agreement: 25 November 2014				
5. Programme title: NVS, Yellow Fever Routine				
6. Vaccine type: Yellow Fever				
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 doses per vial, LYOPHILISED				
8. Programme duration¹⁶: 2001 – 2017				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2001 – 2015	2016	2017	Total ¹⁷
Programme Budget (US\$)	398,910 ¹⁸	55,000	3,149,500	3,603,410
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement): ¹⁹				
Type of supplies to be purchased with Gavi funds in each year	2001 - 2015	2016		
Number of Yellow Fever vaccine doses		51,000		
Number of AD syringes		46,600		
Number of re-constitution syringes		7,600		
Annual Amounts (US\$)	398,910 ²⁰	55,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				

¹⁶ This is the entire duration of the Programme.

¹⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹⁸ This is the consolidated amount for all previous years.

¹⁹ This is the amount that Gavi has approved.

²⁰ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable									
<p>14. Co-financing obligations: Reference code: 16-KEN-06b-X-C</p> <p>According to the co-financing policy, the Country falls within the group Preparatory transition.</p> <p>The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant fiscal year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2016 – 2017</td> </tr> <tr> <td>Number of vaccine doses</td> <td>17,700</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>17,544</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>18,900</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2016 – 2017	Number of vaccine doses	17,700	Value of vaccine doses (US\$)	17,544	Total co-financing payments (US\$) (including freight)	18,900
Type of supplies to be purchased with Country funds in each year	2016 – 2017								
Number of vaccine doses	17,700								
Value of vaccine doses (US\$)	17,544								
Total co-financing payments (US\$) (including freight)	18,900								
15. Operational support for campaigns: Not applicable									
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May, annually</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May, annually	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat		
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May, annually								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
17. Financial clarifications: Not applicable									
<p>18. Other conditions:</p> <p>There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.</p>									

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
26 April 2016